SHigh-throughput Screening
Genetic and small-molecule screens — including CRISPR-based functional genomics — to find combination strategies, resistance mechanisms, and novel targets in PDAC.
Research & Projects
Research programs and clinical trials advancing precision therapeutics in pancreatic and gastrointestinal cancers.
Research Programs
Five interconnected pillars — the sPARK acronym — driving translational breakthroughs in pancreatic ductal adenocarcinoma (PDAC), now extending across gastrointestinal cancers through GRIT (GI RAS Innovative Therapeutics).
PPathology AI
AI-enabled pathology and multimodal data integration to connect tissue phenotypes with therapeutic vulnerabilities in PDAC.
ANeoantigens & Biologics
Pipelines for neoantigen discovery and biologic modalities targeting tumor-specific epitopes.
RDNA Damage Repair & PARP-Immunotherapy
Combining DNA-damage-repair targeting with immunotherapy in BRCA/PALB2-mutated and HRD pancreatic cancer.
Nature Medicine 2026
KKRAS-driven Vulnerabilities
Targeting KRAS G12D — the most common variant in PDAC — with first-in-class degraders and RAS(ON) inhibitors.
NEJM 2026
GRIT — GI RAS Innovative Therapeutics
A cross-tumor initiative extending RAS-directed precision therapy across gastrointestinal cancers — from pancreatic cancer to biliary tract, gastric/GEJ, appendiceal, and colorectal cancer.
Initiative
Biliary Tract Cancer
Extending our KRAS/RAS and precision-oncology work into biliary tract cancer — genomic determinants of chemotherapy benefit today, and RAS-directed trials next.
2026
Trials & Programs
Projects
Named clinical trials and translational efforts — each with its own status, design, and outcomes.
Published
POLAR Trial
Maintenance pembrolizumab + olaparib in HRD metastatic pancreatic cancer
Investigator-initiated phase 2 trial of maintenance pembrolizumab + olaparib in biomarker-stratified metastatic pancreatic cancer.
Active
Setidegrasib (ASP3082)
First-in-human KRAS G12D targeted protein degrader
First-in-human phase 1 trial of setidegrasib, a first-in-class KRAS G12D targeted protein degrader, in advanced PDAC and NSCLC.
Published
Daraxonrasib (RMC-6236)
Oral RAS(ON) multiselective inhibitor
Phase 1–2 study of daraxonrasib, an oral RAS(ON) multiselective inhibitor, in previously treated RAS-mutated pancreatic cancer.
Active
RNA Neoantigen Vaccine
Personalized mRNA vaccines targeting tumor neoantigens
Personalized RNA neoantigen vaccine program priming durable, long-lived T-cell responses in pancreatic cancer.
Explore the sPARK wiki
Every research program, project, publication, journal-club paper and topic, connected. Select a node or browse the node list to explore connections and open its page.
Tap a node to select · use + / − to zoom · enable Move graph to drag